An Open-labeled Trial of Ramipril in Patients With Migraine

Phase 2

Completed

• Conditions: Migraine With Hypertension
• Interventions: Drug: Ramipril

• Registration Number: NCT01402479
• Lead Sponsor: Seoul National University Hospital

Brief Summary

Physiology of migraine involving renin-angiotensin systems (RAS) has been implicated. Ramipril is a broadly-used angiotensin-converting enzyme inhibitor. The investigators attempt to test the efficacy of ramipril on the prophylaxis of migraine attacks.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-10
• Primary Completion: 2005-07
• Study Completion: 2005-07
• Status Verified: 2011-07
• Study First Submitted: 2011-07-24
• Study First Submitted QC: 2011-07-24
• Study First Posted: 2011-07-26
• Last Update Submitted: 2011-08-05
• Last Update Posted: 2011-08-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Patients with chronic migraine are included in this study. Migraineurs should be aged 20 to 70 years old with the ability to read and understand the self-report scales, including the headache diary, used in this study.

Exclusion Criteria

1. Medication overuse headache are excluded in this study.
2. Treatment with other ACEI or medication that may affect ARS
3. Treatment with migraine prophylactic medications or anti-hypertensive agents including β adrenergic receptor or calcium channel blockers
4. Past history of hepatic or renal dysfunction; an abnormal electrocardiography; a psychiatric disorder; a history of substance abuse; pregnancy or lactation; use of anti-psychotics, antidepressants, or anti-anxiety drugs.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
ramipril	Ramipril	open label single arm trial

Primary Outcome Measures

Name	Time	Method
headache frequency	12 week	headache days

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Korea, Republic of